Silver-N-Heterocyclic Complexes Against Leishmania major: In Vitro, In Vivo and In Silico Therapeutic Activities

Basit Öğe Kaydı
dc.contributor.authorSahin, Neslihan
dc.contributor.authorPolat, Zubeyda Akin
dc.contributor.authorGulpinar, Derya Gul
dc.contributor.authorAtas, Ahmet Duran
dc.contributor.authorUstun, Elvan
dc.contributor.authorOzdemir, Ismail
dc.contributor.authorSemeril, David
dc.date.accessioned2026-06-19T06:37:40Z
dc.date.available2026-06-19T06:37:40Z
dc.date.issued2026
dc.departmentMalatya Turgut Özal Üniversitesi
dc.description.abstractBackground/Objectives: Cutaneous leishmaniasis (CL) is a prevalent vector-borne disease characterized by a broad spectrum of clinical manifestations resulting from protozoan parasites belonging to the genus Leishmania. The challenges associated with the treatment of CL are attributable to various factors, including but not limited to: drug resistance, the adverse effects of conventional therapeutic interventions and the imperative for novel therapeutic alternatives to address the global health burden posed by this neglected tropical disease. Methods: In this study, The therapeutic efficacy of two silver(I)-N-heterocyclic carbene (NHC) complexes, namely chloro[1-methallyl-3-(2,4,6-trimethylbenzyl)-5,6-dimethylbenzimidazole-2-ylidene]silver(I) (2a) and chloro[1-methallyl-3-(4-chlorobenzyl)-5,6-dimethylbenzimidazole-2-ylidene]silver(I) (2b), was evaluated against promastigotes in vitro and in vivo in an experimentally induced CL model in Balb/c mice. Results: The findings of this study indicated that these compounds possess the potential to function as effective therapeutic agents, particularly in the treatment of CL. Subsequently, the silver(I) complexes were analyzed by means of molecular docking against LaGP63, LaARG, N-myristoyltransferase and farnesyl pyrophosphate synthase. Conclusions: According to the docking evaluations, complex 2a emerged as the most notable molecule in terms of its potential antileishmanial activity.
dc.identifier.doi10.3390/ph19030356
dc.identifier.issn1424-8247
dc.identifier.issue3
dc.identifier.pmid41901203
dc.identifier.scopus2-s2.0-105034301338
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org/10.3390/ph19030356
dc.identifier.urihttps://hdl.handle.net/20.500.12899/5156
dc.identifier.volume19
dc.identifier.wosWOS:001725400100001
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherMdpi
dc.relation.ispartofPharmaceuticals
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WOS_20260612
dc.subjectCutaneous Leishmaniasis
dc.subjectIn Vivo
dc.subjectIn Vitro
dc.subjectIn Silico
dc.subjectN-Heterocyclic Carbene
dc.subjectSilver Complex
dc.subjectMolecular Docking
dc.titleSilver-N-Heterocyclic Complexes Against Leishmania major: In Vitro, In Vivo and In Silico Therapeutic Activities
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu